<DOC>
	<DOC>NCT01342939</DOC>
	<brief_summary>The purpose of this study is to describe the incretin effect and postprandial incretin response in patients with MODY2 and MODY3 and a group of matched healthy subjects. In sulphonyl urea treated subjects the purpose is also to compare the incretin effect with and without treatment. In healthy subjects the purpose is also to investigate the incretin effect under increased levels of endogen incretin hormones.</brief_summary>
	<brief_title>Pathophysiological Implications of the Incretin Hormones in Maturity Onset of Diabetes of the Young (MODY)</brief_title>
	<detailed_description>Comparison of of insulin secretion (AUC) during the experimental days. Furthermore a comparison of GIP, GLP1 and glucagon responses as well as plasma glucose levels.</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<mesh_term>Gastric Inhibitory Polypeptide</mesh_term>
	<mesh_term>Incretins</mesh_term>
	<criteria>Caucasians above 18 years BMI &gt; 19 kg/m2 Negative pancreatic beta cell and glutamate decarboxylase65(GAD65) autoantibodies Normal haemoglobin Normal bloodpressure Informed concent Known liver disease or affected liver enzymes (ALAT/ASAT &gt;2 x upper normal limit) Nephropathy (see creatinine&gt; 130 Î¼M and / or albuminuria) Treatment with medications that cannot be discontinued for 12 hours Any condition that the investigators feel would interfere with trial participation Pregnancy or lactation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>Monogenetic diabetes</keyword>
	<keyword>Diabetes mellitus</keyword>
</DOC>